tiprankstipranks
Celldex Shareholders Approve Key Governance Changes
Company Announcements

Celldex Shareholders Approve Key Governance Changes

Don't Miss our Black Friday Offers:

Celldex (CLDX) has shared an update.

Celldex Therapeutics, Inc. stockholders, at their 2024 Annual Meeting, endorsed a key amendment expanding the stock pool by 3.2 million shares for their 2021 Omnibus Equity Incentive Plan and raised the award limit for non-employee directors. Additionally, they elected a slate of directors, ratified PricewaterhouseCoopers LLP as their independent auditor, and on an advisory basis, approved executive compensation. These decisions are set to influence the company’s governance and strategic incentive mechanisms moving forward.

Find detailed analytics on CLDX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCelldex announces first patient dosed in Phase 1a study of CDX-622
TipRanks Auto-Generated NewsdeskCelldex Therapeutics Reports Q3 2024 Progress and Financials
Ryan AdistCLDX Upcoming Earnings Report: What to Expect?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App